Monthly EGBLYSS maintenance dosing sustained clear or almost-clear skin for up to three years in the vast majority of ADvocate 1 and 2 responders Nearly 87 percent of patients taking EBGLYSS did not require either high-potency topical corticosteroids or systemic treatments during the three-year studyThe safety profile at three years was consistent with the previously published two-year resultsINDIANAPOLIS, Sept. 25, 2024 /PRNewswire/ -- More than 80 percent of adults and adolescents with moderate-to-severe ...